Ontario expanding safe use of biosimilars

20 December 2022 - Transitioning to biosimilars will allow province to invest in and improve access to medicines. ...

Read more →

Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy

21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...

Read more →

Medical industry advocates urge Ontario to offer cheaper versions of prescription medications

11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...

Read more →

Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program

5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch ...

Read more →

Quebec announces intention to implement a biosimilar switching policy

18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...

Read more →

Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars

18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...

Read more →

Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))

17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the ...

Read more →

Alberta, Canada, begins mandating switches from originator to biosimilar Humira

6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...

Read more →

Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program

28 April 2021 - Additional provincial coverage expected to follow. ...

Read more →

New Brunswick becomes third province in Canada to implement biosimilar switching policy

21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...

Read more →

Fresenius Kabi Canada launches Idacio (adalimumab injection) a biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory conditions

18 February 2021 - Biosimilars offer patients access to affordable, meaningful medicines ...

Read more →

Alberta, Canada sees early success from switching patients to biosimilars

5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...

Read more →

Launch of two biosimilars

19 August 2020 - Sandoz Canada announces an agreement with the pCPA and the launches of Ziextenzo and Riximyo. ...

Read more →

Sandoz Canada launches the biosimilars generation

25 June 2020 - Campaign provides needed, fact-based, information for patients, healthcare providers and Canadians about biosimilar medicines in Canada. ...

Read more →

Rising costs explain why Canada is switching to biosimilars

15 June 2020 - Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars ...

Read more →